BAYRY and BAYN Related Headlines
Go Back- Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
- ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
- Bayer to present cancer trial data at ASCO 2026 meeting
- ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
- Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment
- Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
- FDA grants priority review for Bayer's asundexian stroke drug
- Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
- FDA grants priority review for Bayer's HYRNUO lung cancer application
- U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
- AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
- Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
- Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
- Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
- Bayer to acquire Perfuse Therapeutics for up to $2.45 billion
- Bayer to acquire Perfuse Therapeutics for up to $2.45 billion
- Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
- Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
- New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
- Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class
- Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential
- Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
- Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
- Bayer Crop Science Launches 2026 Opportunity Scholarship Program
- KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
- FDA clears Bayer's MEDRAD MRXperion system for 7T MRI compatibility
- New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
- Bayer reports phase I results for prostate cancer therapy
- Bayer Reports Results for the Investigational Targeted Radionuclide Therapy ²²⁵Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
- Bayer's XOFIGO plus enzalutamide reduces death risk by 24% in prostate cancer
- Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bo
- Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
- Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
- Bayer's asundexian reduces stroke risk by 26% in phase III trial
- Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus
- Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
- Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
- Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
- Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
- Bayer Accelerates Pharma Growth on High-Value Portfolio
- Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Men
- Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
- Bayer partners with Souffle Therapeutics for heart disease siRNA therapy
- Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
- Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference
- Introducing Sivanto Energy: Enhanced Flea Beetle Control
- Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
- RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
- Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
- Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
- Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
- Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
- FDA approves Bayer's HYRNUO for HER2-mutated lung cancer treatment
- U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
- Bayer appoints Dr. Judith Hartmann as new CFO effective June 2026
- Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
- KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
- Bayer receives FDA approval for Lynkuet menopause hot flash treatment
- Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
- Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
- Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
- One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
- BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
- Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
- Bayer Canada Announces New Distribution Partnership for ADALAT® XL® (nifedipine extended-release tablets) 30 mg Tablets in Canada
- Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
- Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
- 10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign
- Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
- Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
- Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
BAYRY and BAYN Related Press Releases
Go Back- Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
- ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
- ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
- Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
- Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
- U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
- AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
- Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
- Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
- Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
- Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
- Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
- New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
- Bayer Canada Supports New School of Medicine at Simon Fraser University (SFU) With Full Tuition Entrance Award for Inaugural Class
- Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential
- Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative
- Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
- Bayer Crop Science Launches 2026 Opportunity Scholarship Program
- KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
- New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
- Bayer Reports Results for the Investigational Targeted Radionuclide Therapy ²²⁵Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
- Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bo
- Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
- Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
- Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus
- Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
- Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
- Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
- Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
- Bayer Accelerates Pharma Growth on High-Value Portfolio
- Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Men
- Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
- Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
- Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference
- Introducing Sivanto Energy: Enhanced Flea Beetle Control
- Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
- RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
- Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
- Bayer Crop Science Canada Launches EverGol Rise for Enhanced User Experience in Pulse Disease Control
- Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
- Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
- U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
- Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
- KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
- Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
- Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
- Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
- One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
- BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
- Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
- Bayer Canada Announces New Distribution Partnership for ADALAT® XL® (nifedipine extended-release tablets) 30 mg Tablets in Canada
- Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
- Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
- 10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign
- Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
- Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
- Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
